← All trials
NCT07155525
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2025
- Primary completion
- Sep 15, 2028
- Completion date
- Nov 15, 2028
- First posted
- Sep 4, 2025
- Last posted
- Sep 18, 2025
- Enrollment
- 194
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Minia UniversityLead sponsor
- Minia UniversityOfficial
- Minia UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.